Cystic fibrosis (CF), the most common inherited disease in Caucasians, is caused by mutations in CFTR, the most frequent of which is F508del. F508del causes ER retention and degradation of the mutant CFTR protein, but also defective channel gating and decreased half-life at the plasma membrane. Despite the recent successes with small-molecule CFTR modulator drugs, the folding-corrector/gating-potentiator drug combinations approved for CF individuals carrying F508del-CFTR have sometimes produced severe side effects. Previously, we showed that a prolonged, 15-days treatment of polarized bronchial epithelial monolayers with the VX-809+VX-770 combination resulted in epithelial dedifferentiation effects that we found were caused specifically by VX-809. Moreover, prolonged VX-770 exposure also led to the destabilization of VX-809-rescued F508del-CFTR. Notably, co-treatment with the physiological factor HGF prevented VX-809-mediated epithelial differentiation and reverted the destabilizing effect of VX-770 on VX-809-rescued CFTR. Here, we show that prolonged treatment with VX-661, a second-generation corrector developed based on VX-809 structure, does not perturb epithelial integrity of polarized bronchial epithelial monolayers. Yet, its efficacy is still affected by co-exposure to VX-770, the potentiator present in all VX-661-containing combination therapies approved in the United States and Europe for treatment of F508del-CFTR carriers. Importantly, we found that co-treatment with HGF still ameliorated the impact of VX-770 in F508del-CFTR functional rescue by VX-661, without increasing cell proliferation (Ki-67) or altering the overall expression of epithelial markers (ZO-1, E-cadherin, CK8, CK18). Our findings highlight the importance of evaluating the cellular effects of prolonged exposure to CFTR modulators and suggest that the benefits of adding HGF to current combination therapies should be further investigated.

Keywords: cystic fibrosis, CFTR modulators, VX-661 corrector, prolonged chronic treatment, HGF
INTRODUCTION

Cystic fibrosis (CF) is one of the most common life-shortening inherited diseases in Caucasian populations (De Boeck, 2020). CF is a monogenic disease caused by mutations in CF transmembrane conductance regulator (CFTR) gene (Saint-Criq and Gray, 2017). It encodes the CFTR protein, an anion channel expressed at the apical plasma membrane (PM) of epithelial cells, responsible for the transport of chloride and bicarbonate across different epithelia (Saint-Criq and Gray, 2017; De Boeck, 2020). The most frequent mutation, F508del, is present in at least one allele of 80–85% of CF individuals worldwide and causes the protein to misfold and be prematurely degraded by the ER quality control mechanism (ERQC) (Farinha and Matos, 2016). The very few F508del-CFTR molecules that manage to escape ERQC in CF cells bare a deficiency in channel gating, and a highly decreased half-life at the PM of epithelial cells (Farinha et al., 2013; Farinha and Matos, 2016; Loureiro et al., 2019).

Clinically, CF presents as a complex multi-organ disorder, but the respiratory complications are the disease’s major cause of morbidity and premature death (De Boeck, 2020; McBennett et al., 2021). Despite significant clinical progress in the last decades, with symptomatic therapies enabling the delay of disease progression, CF individuals inevitably develop severe chronic complications, particularly in the lungs, which greatly impact their quality of life and life expectancy (Saint-Criq and Gray, 2017; McBennett et al., 2021).

More recently, several studies using high-throughput screens of small-molecule libraries have led to the identification of selective CFTR modulator compounds capable of directly targeting the molecular defects on mutant CFTR proteins (Lopes-Pacheco et al., 2021). Several of these modulator drugs are now approved for clinical use in individuals with specific CF genotypes (Meoli et al., 2021). Such is the case of Orkambi®, approved by Federal Drug Administration (FDA) and European Medical Agency (EMA) in 2015 for adult CF patients and in 2018 for CF children aged 2 years and older, who are homozygous for the F508del-CFTR mutation (Boyle et al., 2014). Orkambi® consists in the combination of a small-molecule CFTR corrector (a drug that facilitates CFTR protein folding, processing, and trafficking to the cell surface), named Lumacaftor (also known as VX-809) and a potentiator (a drug that improves the conductance of ions through CFTR already at the PM, maintaining the channel in an open conformation), named Ivacaftor (also known as VX-770) (Lopes-Pacheco et al., 2021). Unfortunately, the clinical response to the VX-809+VX-770 combination therapy was, at best, modest (Hubert et al., 2017; McNamara et al., 2019), with frequent respiratory adverse effects (AEs) and drug intolerance reports, leading to discontinuation of
the treatment in several cases (McNamara et al., 2019). This limited efficacy of combination therapy has been partially attributed to pharmacological incompatibilities between the two drugs. Chronic VX-770 exposure reduces F508del-CFTR correction by VX-809 in CF cells, whereas VX-809 reduces plasma concentration of VX-770 through the induction of cytochrome CYP3A4 activity (Cholon et al., 2014; Schneider, 2018). However, in previous work we found that prolonged (15-days) exposure to VX-809 resulted in the dedifferentiation of epithelium-like polarized cell monolayers from both lung and intestinal origin, which represent the two systems most affected by AEs in patients treated with VX-809 or the VX-809+VX-770 combination (Matos et al., 2018). Moreover, we demonstrated that the co-treatment with hepatocyte growth factor (HGF) prevented VX-809-induced epithelial dedifferentiation and significantly improved the functional rescue of F508del-CFTR by the VX-809 +VX-770 combination. Part of this improvement resulted from HGF preventing VX-770 from destabilizing VX-809-rescued F508del-CFTR at the PM, increasing the levels of rescued matured channel (the higher molecular weight, fully glycosylated CFTR band C in immunoblots) (Moniz et al., 2013; Matos et al., 2018). More recently, a second corrector/potentiator therapy was approved for clinical use by FDA and EMA, with the commercial designations of Symdeko ® and Symkevi ®, respectively (Meoli et al., 2021). These drugs are a combination of VX-770 with Tezacaftor (VX-661), a second-generation corrector developed based on VX-809 structure but exhibiting better pharmacokinetic properties and fewer AEs reported in clinical trials (Donaldson et al., 2018; Meoli et al., 2021). The VX-661+VX-770 combination demonstrated comparable therapeutic efficacy to VX-809 + VX770 in F508del-homozygous patients (Taylor-Cousar et al., 2017) but...
produced improved outcomes in certain CF individuals heterozygous for F508del, in comparison to treatment with VX-770 alone (Rowe et al., 2017). At present this combination is indicated in the United States and Europe for CF individuals aged 6 years and older, homozygous for the F508del mutation or heterozygous for the F508del mutation with one of several residual function mutations (Meoli et al., 2021). Another combination drug, named Trikafta™, that combines an additional corrector, VX-445 (elexacaftor), with VX-661 and VX-770, has shown improved responses in patients with the mutation F508del in at least one allele, and has been recently approved by the FDA for the treatment of CF patients aged 6 years or older (Meoli et al., 2021). We, therefore, found it important to clarify whether the prolonged exposure to the core VX-661+VX-770 combination common to all these drugs had similar epithelial dedifferentiation effects to those found for the VX-809+VX-770 combination. Moreover, we also further investigated if co-treatment with HGF could also ameliorate any potential deleterious effects of prolonged VX-661+VX-770 treatment, and whether it also improve F508del-CFTR functional rescue in polarized epithelial airway cells.

MATERIALS AND METHODS

Cell Culture and Treatment

CFBE41o-cells stably expressing F508del-CFTR and stably co-expressing F508del-CFTR and the YFPF46L/H148Q/I152L halide sensor were generated and cultured as previously described (Matos et al., 2018). Cell monolayers were polarized in transwell porous (1 μm) PET filter inserts (Ø 6.4 mm, from Falcon—Thermo Fisher Scientific), pre-coated with collagen IV and fibronectin (both Thermo Fisher Scientific), and cultured in medium supplemented with 5% fetal bovine serum (FBS, Thermo Fisher Scientific), until they reached a transepithelial electrical resistance (TEER) above 600 Ω, as measured with a Chopstick Electrode (STX2 from WPI). Cells were then treated for the indicated periods, with DMSO (Sigma Aldrich) or the described concentrations of recombinant human HGF (Santa Cruz Biotechnology), VX-809, VX-770, VX-661 (Selleck Chemicals), CFTR inhibitor-172 (inh-172; CFFT United States), or forskolin (Fsk; Sigma-Aldrich). All stock solutions were made 103 times concentrated, dissolved in DMSO.

CFTR Functional Assay by Halide-Sensitive YFP

CFTR activity was determined using F508del-CFTR/HS-YFP CFBE cells polarized in transwell filter inserts, as described above. Cells were treated for 15 days with the indicated compound concentrations. Cells were then washed with PBS and incubated for 30 min in PBS containing compounds for CFTR stimulation/inhibition [Fsk, or Fsk + acVX-770 (acutely added), or inh172] at the indicated concentrations. HS-YFP fluorescence decay in polarized cells was then analyzed as previously described (Matos et al., 2018). Briefly, after stimulation, inserts were transferred to a holding chamber on top of a glass slide that can be positioned on a Leica TCS-SPE
confocal microscope for time-lapse analysis. Filters were assayed individually at room temperature for iodide influx by recording fluorescence continuously (500 ms/point) for 10 s (baseline) and then for 50 s after the rapid (<1 s) apical addition, through a Ø 0.5 mm steel tubing clamp, of isomolar PBS in which 137 mM Cl\(^-\) was replaced by I\(^-\) (PBSI, final NaI concentration in the well: 100 mM). After background subtraction, cell fluorescence recordings were normalized for the initial average value measured before addition of I\(^-\). Quantification of fluorescence decay was performed on at least 30 individual cells per filter, using ImageJ software (NIH) as previously described (Matos et al., 2018). The initial rate of fluorescence decay (QR), an indicator of the rate of halide transport by CFTR (Galietta et al., 2001), was derived by fitting the curves to exponential decay function using GraphPad 5.0.

**Immunoblotting and Immunofluorescence**

Samples were analyzed by immunoblotting as previously described (Matos et al., 2018; Loureiro et al., 2019). Antibodies used for WB were: mouse anti-CFTR clone 596 (obtained through the UNC CFTR antibody distribution program sponsored by CFFT), mouse anti-α-Tubulin clone B-5-1-2 (Sigma-Aldrich), mouse anti-β-Actin (Millipore), mouse anti-E-cadherin (Transduction Laboratories), mouse anti-CK18 (Millipore), rabbit anti-ZO-1, mouse anti-CK8 and rabbit anti-Ki-67 (all from Santa Cruz Biotechnology). Primary antibodies were detected using secondary, peroxidase-conjugated antibodies (Bio-Rad) followed by ECL. For densitometric analysis of WB bands, x-rays films were digitalized and images analyzed with ImageJ software (NIH).

For immunofluorescence analysis, cells grown on filters were fixed with 4% formaldehyde, washed with PBS, permeabilized with 0.2% Triton X-100 (Sigma-Aldrich), and incubated for 1 h with mouse anti-CFTR clone 570 (obtained through the UNC CFTR antibody distribution program sponsored by CFFT). Cells were then thoroughly washed with PBS and incubated for 30 min with AlexaFluor488-conjugated secondary antibody (Life Technologies Invitrogen Corporation). Actin was stained using phalloidin-TRITC (Jackson ImmunoResearch Laboratories), followed by thorough washing in PBS and DAPI staining of nuclei. Filters were mounted on microscope slides with Vectashield (Vector Laboratories), covered with coverslips and...
RESULTS AND DISCUSSION

In Contrast to VX-809, Prolonged Treatment With VX-661 Does not Compromise Epithelial Integrity of Polarized Bronchial Epithelial Cells

We previously described that a prolonged, 15-days treatment of polarized bronchial epithelial cells with the VX-809 corrector drug led to formerly unrecognized epithelial dedifferentiation effects (Matos et al., 2018). In contrast to the commonly used 48 h in vitro treatments, prolonged exposure of F508del-CFTR-expressing CFBE cells to 3 µM VX-809 resulted in decreased transepithelial resistance and concomitant downregulation of epithelial differentiation markers, namely the tight junction protein Zonula occludens-1 (ZO-1) (Martin and Jiang, 2009) and the pro-differentiation marker cytokeratin 18 (CK18) (Zhang et al., 2014), whereas the lung cancer pro-dedifferentiation marker cytokeratin 8 (CK8) (Fukunaga et al., 2002) became upregulated (Matos et al., 2018).

We therefore investigated whether the prolonged exposure of polarized F508del-CFBE cells to VX-661 had similar epithelial differentiation effects to VX-809. We found that in contrast to VX-809 treatment, which progressively decreased TEER reaching a significant reduction over control conditions at 12 days of treatment, TEER values for VX-661-treated cells showed no significant difference from control cells during the entire 15 days of treatment and were significantly higher than VX-809-treated cells at day 15 (Figure 1A). Moreover, whereas ZO-1 and CK18 levels were significantly decreased after 15 days in VX-809-treated cells, the levels of these epithelial markers in VX-661-treated cells remained comparable to those of control cells (Figures 1B,C). Both these observations are consistent with VX-661 having a better safety profile, with far less adverse effects, respiratory and otherwise, in clinical trials (Taylor-Cousar et al., 2017; Donaldson et al., 2018) and after continued clinical use (Gavioli et al., 2021; Paterson et al., 2021).

In addition, we observed that prolonged treatment with VX-661 elicited an apparent improved rescue of F508del-CFTR (rF508del) in polarized CFBE cells compared to VX-809 (Figures 1B,C). By immunolabeling polarized CFBE cells treated with either vehicle (DMSO), or 3 µM of either VX-809 or VX-661 for 15 days, we could observe that exposure to VX-661 resulted in a clearly better structured epithelial-like monolayer, when compared to VX-809, and also elicited apparent stronger CFTR staining at the apical membrane of the polarized cell monolayer (Figure 2A). Using a previously described methodology (Loureiro et al., 2019) to quantify apical (AP), basolateral (BL) and total (TL = AP + BL) immunofluorescent CFTR signals, we confirmed that, despite producing equivalent levels of total rF508del protein, prolonged treatment with VX-661 resulted in a small (~1.5-fold) but significant (p < 0.05) increase in apical rF508del abundance over that produced by equivalent treatment with VX-809 (Figure 2B). Repeating these experiments using the previously characterized model of polarized CFBE cell co-expressing F508del-CFTR and the YFP-P46L/H148Q/I152L halide sensor (Matos et al., 2018; Loureiro et al., 2019) allowed us to confirm that forskolin-stimulated activity of CFTR was indeed higher in VX-661-treated cells, although not sufficient to reach statistical significance over cells similarly treated with VX-809 (Figures 2C,D). In both cases, CFTR activity was similarly inhibited by the presence of CFTR inhibitor 172 (inh172; Figures 2C,D).

Co-Treatment with HGF Prevents Apical Levels of VX-661-Rescued F508del-CFTR From Decreasing During Chronic Exposure to VX-770 Potentiator

We previously showed that co-treatment with 50 ng/ml HGF could ameliorate the differentiation effects of prolonged VX-809 exposure, also enhancing the rescue of F508del-CFTR by the corrector in polarized CFBE cells (Matos et al., 2018). Postulating that the two effects could be related, we investigated whether HGF would also enhance the activity of VX-661 in these cells. Interestingly, although we confirmed that the prolonged treatment with HGF did not alter the proliferative potential of these cells (assessed through the levels of proliferation marker Ki-67; Figures 3A,B), when comparing VX-661 + HGF co-treated cells to cells treated with VX-661 alone (Figures 3A,B), we observed no improvement in rF508del levels nor any significant change in the abundance of epithelial markers, including ZO-1, E-cadherin (E-cad), CK18 or CK8.

However, as mentioned above, F508del correctors are usually administered in combination with potentiator drugs, namely VX-770, to improve the rescued channels’ impaired gating (Meoli et al., 2021). We found that, as was described for VX-809 (Cholon et al., 2014; Veit et al., 2014; Matos et al., 2018), chronic (15 days) co-exposure to 1 µM VX-770 significantly (p < 0.01) reduces VX-661-rescued CFTR in F508del-expressing cells (Figures 3A,B). However, we found that co-administration of HGF restored rF508del abundance in VX-661+VX-770-treated cells to levels equivalent to cells treated with VX-661 alone (Figures 3A,B). This is consistent with the described role of HGF in improving the stability of rescued F508del-CFTR at the cells’ membrane (Moniz et al., 2013; Matos et al., 2018). Indeed, analysis of CFTR subcellular distribution in cells treated in these conditions clearly showed a significant decrease in apical localization of VX-661-rescued F508del-CFTR upon prolonged co-treatment with VX-770, which was completely reversed, and even favored, in the presence of HGF (Figures 4A,B). Importantly, iodide influx assays showed that this restoration of apical
localization was sufficient to recover CFTR-mediated ion transport in chronic VX-661+VX-770 + HGF co-treated cells to levels equivalent to those of cells treated with VX-661 alone and acutely stimulated with 10 µM of VX-770 for 30 min (Figures 4C,D).

Conclusion
Taken together, our results suggest that, as proposed for VX-809-based combination therapies (Matos et al., 2018), HGF co-treatment would also favor therapeutic regimens employing the chronic co-administration of VX-661 and VX-770, namely Symdeko®/Symkevi® (United States and Europe commercial designations, respectively), currently approved for patients aged ≥6 years, homozygous for the F508del mutation or heterozygous for the F508del mutation and one of several residual function mutations (Meoli et al., 2021). While the physiologic significance of our findings is limited by the use of in vitro models, these should stimulate the CF scientific community to further address the potential gains of adding HGF to current CFTR modulator combinational therapies, namely by using currently available in vivo and ex vivo (patient-derived tissues and organoids) models. Supportive of a potential application of HGF in the CF setting, several in vivo studies indicated that HGF administration can mitigate the effects of acute and chronic lung injuries (Panganiban and Day, 2011), having beneficial effects both at the initial and late stages of lung disease (Yaekashiwa et al., 1997; Panganiban and Day, 2011). Moreover, HGF was shown to inhibit amiloride-sensitive epithelia Na⁺ channel (ENaC) function in CF airway epithelium (Shen, Widdicombe, and Mrsn 1999), suggesting that its administration could also be beneficial to reduce the abnormally high activity of ENaC observed in CF airway cells. In future studies, it will be interesting to ascertain if HGF can also improve the activity of the very recently approved triple combination of VX-661+VX-770 with VX-445, which has already shown better clinical responses (Meoli et al., 2021).

DATA AVAILABILITY STATEMENT
The original contributions presented in the study are included in the article/Supplementary Material, further inquiries can be directed to the corresponding author.

AUTHOR CONTRIBUTIONS
AM and PM designed research; AM performed the experiments; AM and PM analysed the data; PM and PJ procured the funding and wrote the paper.

FUNDING
This work was supported by the Grant PTDC/BIÁ-CEL/28408/2017 (to PJ and PM) and Center Grant UID/MULTI/04046/2019 to BioISI, both from the Portuguese Fundação para a Ciência e a Tecnologia.

ACKNOWLEDGMENTS
The authors thank Patrícia Barros (Instituto Nacional de Saúde Doutor Ricardo Jorge/BioISI) for insightful discussions and her help in revising the manuscript.

REFERENCES
Boyle, M. P., Bell, S. C., Konstan, M. W., McColley, S. A., Rowe, S. M., Rietschel, E., et al. (2014). A CFTR corrector (lumacaftor) and a CFTR potentiator (ivacaftor) for treatment of patients with cystic fibrosis who have phe508del CFTR mutation: a phase 2 randomised controlled trial. Lancet Respir. Med. 2, 527–538. doi:10.1016/S2213-2600(14)70132-8
Cholon, D. M., Quinnney, N. L., Fulcher, M. L., Esther, C. R., Das, J., Dokholyan, N. V., et al. (2014). Potentiator Ivacaftor Abrogates Pharmacological Correction of ΔF508 CFTR in Cystic Fibrosis. Sci. Transl. Med. 6, 246ra96. doi:10.1126/scitranslmed.3008680
De Boeck, K. (2020). Cystic Fibrosis in the Year 2020: A Disease with a New Face. Acta Paediatr. 109, 893–899. doi:10.1111/apa.15155
Donaldson, S. H., Pilewski, J. M., Griese, M., Cooke, J., Viswanathan, L., Tullis, E., et al. (2018). Tezacaftor/Ivacaftor in Subjects with Cystic Fibrosis and F508del/ F508del-CFTR or F508del/G551D-CFTR. Am. J. Respir. Crit. Care Med. 197, 214–224. doi:10.1164/rccm.201704-0717OC
Farinha, C. M., Matos, P., and Amaral, M. D. (2013). Control of Cystic Fibrosis Transmembrane Conductance Regulator Membrane Trafﬁcking; Not Just from the Endoplasmic Reticulum to the Golgi. FEBS J. 280, 4396–4406. doi:10.1111/ feds.12392
Farinha, C. M., and Matos, P. (2016). Repairing the Basic Defect in Cystic Fibrosis - One Approach Is Not Enough. FEBS J. 283, 246–264. doi:10.1111/febs.13531
Fukunaga, Y., Bandoh, S., Fujita, J., Yang, Y., Ueda, Y., Hojo, S., et al. (2002). Expression of Cytokeratin 8 in Lung Cancer Cell Lines and Measurement of Serum Cytokeratin 8 in Lung Cancer Patients. Lung Cancer 38, 31–38. doi:10.1016/s0169-5002(02)00109-5
Galiotta, L. J. V., Haggie, P. M., and Verkman, A. S. (2001). Green Fluorescent Protein-Based Halide Indicators with Improved Chloride and Iodide Affinities. FEBS Lett. 499, 220–224. doi:10.1016/s0014-5793(01)02561-3
Gavioli, E. M., Guardado, N., Haniff, F., Deiab, N., and Vider, E. (2021). A Current Review of the Safety of Cystic Fibrosis Transmembrane Conductance Regulator Modulators. J. Clin. Pharm. Ther. 46, 286–294. doi:10.1111/jcpt.13329
Hubert, D., Chiron, R., Camara, B., Grenet, D., Prévotat, A., Bassinet, L., et al. (2017). Real-life initiation of lumacaftor/ivacaftor combination in adults with cystic fibrosis homozygous for the F508del CFTR mutation and severe lung disease. J. Cystic Fibrosis 16, 388–391. doi:10.1016/j.jcf.2017.03.003
Lopes-Pacheco, M., Pedemonte, N., and Veit, G. (2021). Discovery of CFTR Modulators for the Treatment of Cystic Fibrosis. Expert Opin. Drug Discov. 16, 1–17. doi:10.1080/17460441.2021.1912732
Loureiro, C. A., Santos, J. D., Matos, A. M., Jordan, P., Matos, P., Farinha, C. M., et al. (2019). Network Biology Identifies Novel Regulators of CFTR Trafficking and Membrane Stability. Front. Pharmacol. 10, 619. doi:10.3389/fphar.2019.00619
Martin, T. A., and Jiang, W. G. (2009). Loss of Tight junction Barrier Function and its Role in Cancer Metastasis. Biochim. Biophys. Acta (Bba) - Biomembranes 1788, 872–891. doi:10.1016/j.bbamem.2008.11.005
Matos, A. M., Gomes-Duarte, A., Faria, M., Barros, P., Jordan, P., Amaral, M. D., et al. (2018). Prolonged Co-treatment with HGF Sustains Epithelial Integrity and Improves Pharmacological rescue of Phe508del-CFTR. Sci. Rep. 8, 13026. doi:10.1038/s41598-018-31514-2
McBennett, K. A., Davis, P. B., and Konstan, M. W. (2021). Increasing Life Expectancy in Cystic Fibrosis: Advances and Challenges. Pediatr. Pulmonology, 1–8. doi:10.1002/ppul.25733

McNamara, J. J., McColley, S. A., Marigowda, G., Liu, F., Tian, S., Owen, C. A., et al. (2019). Safety, Pharmacokinetics, and Pharmacodynamics of Lumacaftor and Ivacaftor Combination Therapy in Children Aged 2-5 Years with Cystic Fibrosis Homozygous for F508del-CFTR: an Open-Label Phase 3 Study. Lancet Respir. Med. 7, 325–335. doi:10.1016/S2213-2600(18)30460-0

Meoli, A., Fainardi, V., Deolmi, M., Chiopris, G., Marinelli, F., Caminiti, C., et al. (2021). State of the Art on Approved Cystic Fibrosis Transmembrane Conductance Regulator (CFTR) Modulators and Triple-Combination Therapy. Pharmaceutica 14, 928. doi:10.3390/ph14090928

Moniz, S., Sousa, M., Moraes, B. J., Mendes, A. I., Palma, M., Barreto, C., et al. (2013). HGF Stimulation of Rac1 Signaling Enhances Pharmacological Correction of the Most Prevalent Cystic Fibrosis Mutant F508del-CFTR. ACS Chem. Biol. 8, 432–442. doi:10.1021/cb300484r

Panganiban, R. A. M., and Day, R. M. (2011). Hepatocyte Growth Factor in Lung Repair and Pulmonary Fibrosis. Acta Pharmacol. Sin. 32, 12–20. doi:10.1038/aps.2010.90

Paterson, I., Johnson, C., and MacGregor, G. (2021). Tezacaftor-ivacaftor Use in Routine Care of Adults with Cystic Fibrosis: a Medicine Use Evaluation. Eur. J. Hosp. Pharm. [Online ahead of print]. doi:10.1136/ejhpharm-2020-002676

Rowe, S. M., Daines, C., Ringshausen, F. C., Kerem, E., Wilson, J., Tullis, E., et al. (2017). Tezacaftor-Ivacaftor in Residual-Function Heterozygotes with Cystic Fibrosis. N. Engl. J. Med. 377, 2024–2035. doi:10.1056/NEJMoa1709847

Saint-Criq, V., and Gray, M. A. (2017). Role of CFTR in Epithelial Physiology. Cell. Mol. Life Sci. 74, 93–115. doi:10.1007/s00018-016-2391-y

Schneider, E. K. (2018). Cytochrome P450 3A4 Induction: Lumacaftor versus Ivacaftor Potentially Resulting in Significantly Reduced Plasma Concentration of Ivacaftor. Dm1 12, 71–74. doi:10.2174/18723128116666180328105259

Shen, B. Q., Widdicombe, J. H., and Mrsny, R. J. (1999). Hepatocyte Growth Factor Inhibits Amiloride-Sensitive Na+Channel Function in Cystic Fibrosis Airway Epithelium In Vitro. Palm. Pharmacol. Ther. 12, 157–164. doi:10.1006/pupt.1999.9999

Taylor-Cousar, J. L., Munck, A., McKone, E. F., van der Ent, C. K., Moeller, A., Simard, C., et al. (2017). Tezacaftor-Ivacaftor in Patients with Cystic Fibrosis Homozygous for Fhe508del. N. Engl. J. Med. 377, 2013–2023. doi:10.1056/NEJMoa1709846

Veit, G., Avramescu, R. G., Perdomo, D., Phuan, P.-W., Bagdany, M., Apaja, P. M., et al. (2014). Some Gating Potentiators, Including VX-770, Diminish ΔF508-CFTR Functional Expression. Sci. Transl. Med. 6, 246ra97. doi:10.1126/scitranslmed.3008889

Yaekashiwa, M., Nakayama, S., Ohnuma, K., Sakai, T., Abe, T., Satoh, K., et al. (1997). Simultaneous or Delayed Administration of Hepatocyte Growth Factor Equally Represses the Fibrotic Changes in Murine Lung Injury Induced by Bleomycin. Am. J. Respir. Crit. Care Med. 156, 1937–1944. doi:10.1164/ajrccm.156.6.9611057

Zhang, H., Chen, X., Wang, J., Guang, W., Han, W., Zhang, H., et al. (2014). EGRI Decreases the Malignancy of Human Non-small Cell Lung Carcinoma by Regulating KRT18 Expression. Sci. Rep. 4, 5416. doi:10.1038/srep05416

Conflict of Interest: The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.

Publisher’s Note: All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors and the reviewers. Any product that may be evaluated in this article, or claim that may be made by its manufacturer, is not guaranteed or endorsed by the publisher.

Copyright © 2021 Matos, Jordan and Matos. This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.